Top Markets
#1 Trillions Trillions +4,371.27%
#2 Ozapay Ozapay +38.46%
#3 UnifAI Network UnifAI Network +23.35%
#4 Aria.AI Aria.AI +22.13%
#5 Zano Zano +17.76%
#6 Osaka Protocol Osaka Protocol +14.37%
#7 StakeStone StakeStone +14.34%
#8 Vestra DAO Vestra DAO +12.12%
#9 River Pts River Pts +10.84%
#10 Janction Janction +10.23%
Coin of the day
Trillions Trillions
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rangering i aksjer #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Aksjekurs
$0.28545656
Markedsverdi
$4.50M
Endring (1 dag)
5.97%
Endring (1 år)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategori

Healthcare
P/B-forhold for Acticor Biotech SAS (ALACT)
P/B-forhold per March 2026 TTM: -0.57
Ifølge Acticor Biotech SAS sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) -0.57. Ved slutten av 2022 hadde selskapet et P/B-forhold på -33.19.
P/B-historikk for Acticor Biotech SAS fra 2010 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 -1,096.18%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 -1,224.18%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -532.31%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -868.45%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -549.09%
AU